AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18795931 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated ROAT doses (1, 2, and 3 weeks) with MDBGN
Number of subjects: 18
Study 15949196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically stable malarial anaemia
Number of subjects: 255
Study 12053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron specific enolase (NSE) evaluation
Number of subjects: 146
Study 12053589 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study 10689258 — intervention group
Group type: EXPERIMENTAL
Intervention: AVGCS
Number of subjects: 170
Study 10689258 — intervention group
Group type: COMPARATOR
Intervention: Control (uncovered stents)
Number of subjects: 170
Study 9015593 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging protocol (10 min at 60% of maximum age predicted heart rate)
Number of subjects: 24
Study 9015593 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching protocol (five 30 s static stretches with 30 s rest between stretches)
Number of subjects: 24
Study 9015593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol (jogging followed by stretching)
Number of subjects: 24
Study 9015593 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching only protocol
Number of subjects: 24
Study 9015593 — intervention group
Group type: COMPARATOR
Intervention: Running only protocol
Number of subjects: 24
Study 1414430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling session from family physician
Number of subjects: 425
Study 1414430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling session from family physician + free supply of nicotine gum
Number of subjects: 425
Study 1414430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief health-education session from primary care nurse
Number of subjects: 425
Study 4076354 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily structured physical exercise for 10 weeks
Number of subjects: 21
Study 4076354 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily inspiratory muscle training by resistive breathing for 10 weeks
Number of subjects: 21
Study 4076354 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo training for 10 weeks
Number of subjects: 21
Study 4076354 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 21
Study 31656094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 692
Study 31656094 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-protein diet
Number of subjects: 692
Study 31656094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom tertile of SBP/DBP-PGS
Number of subjects: 692
Study 31656094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-diet interaction
Number of subjects: 692
Study 29428926 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory costal manual therapy (AC group)
Number of subjects: 112
Study 29428926 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolymphatic therapy (NL group)
Number of subjects: 112
Study 29428926 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory spinal manual therapy (AS group)
Number of subjects: 112
Study 26782620 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐IMR intervention (e-health application combined with face-to-face delivery of the Illness Management & Recovery programme)
Number of subjects: 0
Study 26782620 — intervention group
Group type: COMPARATOR
Intervention: Illness Management & Recovery programme (control condition)
Number of subjects: 0
Study 24026982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h RFES session from the CAN-FIT programme
Number of subjects: 30
Study 24026982 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 22137666 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐per‐week EPO, 1200 U/kg/dose, subcutaneously for 4 weeks
Number of subjects: 20
Study 22137666 — intervention group
Group type: COMPARATOR
Intervention: 3‐times‐a‐week EPO, 400 U/kg/dose, subcutaneously for 4 weeks
Number of subjects: 20
Study 20730261 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic TENS (n = 13)
Number of subjects: 25
Study 20730261 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (n = 12)
Number of subjects: 25
Study 17688113 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood as a mediator
Number of subjects: 247
Study 17688113 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed model
Number of subjects: 247
Study 15650312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily (bid)
Number of subjects: 206
Study 15650312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 11291084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of synthetic mutant ras peptides with granulocyte-macrophage colony-stimulating factor as adjuvant
Number of subjects: 48
Study 9384020 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized oxygen with antibacterial, antiphlogistic drugs, expectorants, antispastic and antiasthmatic drugs
Number of subjects: 148
Study 9384020 — intervention group
Group type: COMPARATOR
Intervention: Convenient simple aerosolized oxygen inhalation
Number of subjects: 148
Study 8202964 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 to 40 mg/d) for 3 and 6 weeks
Number of subjects: 66
Study 8202964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 3109894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultipor Pall BB50 filter included 'in series' in the Bain circuit
Number of subjects: 81
Study 3109894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filter)
Number of subjects: 81
Study 2239815 — intervention group
Group type: EXPERIMENTAL
Intervention: Yomeishu (YMS) 20 ml twice a day before meals for 12 weeks
Number of subjects: 50
Study 2239815 — intervention group
Group type: EXPERIMENTAL
Intervention: Yomeishu (YMS)
Number of subjects: 50
Study 1093464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide therapy (DAT)
Number of subjects: 13
Study 1093464 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 13
Study 31813354 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged Holter‐ECG monitoring (EPM) (3× 10‐day Holter‐ECG)
Number of subjects: 398
Study 31813354 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke care diagnostic work‐up (Control)
Number of subjects: 398
Study 31775721 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite overlay restoration in normal bone level (Group 1)
Number of subjects: 60
Study 31775721 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite fillings in normal bone level (Group 3)
Number of subjects: 60
Study 31775721 — intervention group
Group type: COMPARATOR
Intervention: Indirect composite overlay restoration in furcation involvement (Group 2)
Number of subjects: 60
Study 31775721 — intervention group
Group type: COMPARATOR
Intervention: Direct composite fillings in furcation involvement (Group 4)
Number of subjects: 60
Study 27805571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 800 mg once a day for 6 days
Number of subjects: 2
Study 27805571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 400 mg twice daily for 6 days
Number of subjects: 2
Study 27805571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 26114120 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week intensive program for diabetes weight management
Number of subjects: 120
Study 23102873 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injected into facial muscles within 72 hours postoperatively.
Number of subjects: 30
Study 23102873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BTA injection).
Number of subjects: 30
Study 23102873 — intervention group
Group type: COMPARATOR
Intervention: Both groups assessed using PSAS, OSAS, and VSS scores.
Number of subjects: 30
Study 21647903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tip projection (NTP) ratios (Goode, Simons, Baum, Powell, Crumley)
Number of subjects: 300
Study 21647903 — intervention group
Group type: EXPERIMENTAL
Intervention: Baum, Powell, and Simons ratios
Number of subjects: 300
Study 21647903 — intervention group
Group type: EXPERIMENTAL
Intervention: Goode and Crumley ratios
Number of subjects: 300
Study 19365652 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels pre-IVIG
Number of subjects: 43
Study 19365652 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels pre-IVIG
Number of subjects: 43
Study 16704952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with 5% energy from fructose (low fruit diet)
Number of subjects: 15
Study 16704952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with 15% energy from fructose (high fruit diet)
Number of subjects: 15
Study 15081455 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg)
Number of subjects: 344
Study 11240959 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT) combined with specific IgE measurement
Number of subjects: 98
Study 11240959 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT)
Number of subjects: 98
Study 11240959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of positive APT results and specific IgE measurement
Number of subjects: 98
Study 9264422 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator placement
Number of subjects: 542
Study 9264422 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (antiarrhythmic drug therapy)
Number of subjects: 542
Study 7899862 — intervention group
Group type: COMPARATOR
Intervention: LAC group
Number of subjects: 58
Study 7899862 — intervention group
Group type: COMPARATOR
Intervention: ET group
Number of subjects: 58
Study 3582605 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCCA (methylprednisolone, vincristine, CCNU, cyclophosphamide, melphalan)
Number of subjects: 130
Study 3582605 — intervention group
Group type: COMPARATOR
Intervention: MP (intermittent melphalan and prednisone)
Number of subjects: 130
Study 31332957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1 (10-week online physical activity program)
Number of subjects: 351
Study 31332957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 (same program plus activity tracker)
Number of subjects: 351
Study 31332957 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 351
Study 29135066 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic monitoring with the AliveCor™ device
Number of subjects: 0
Study 29135066 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac care
Number of subjects: 0
Study 28049642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (10 mg/m2 on days 1-5 of each of both cycles)
Number of subjects: 393
Study 28049642 — intervention group
Group type: COMPARATOR
Intervention: Control (idarubicine-cytarabine and amsacrine-cytarabine without clofarabine)
Number of subjects: 393
Study 28049642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (in subgroup analyses)
Number of subjects: 393
Study 28049642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine
Number of subjects: 393
Study 25982338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol combined with oral prednisolone for the initial 2 weeks
Number of subjects: 40
Study 25982338 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone for 6 months
Number of subjects: 40
Study 23063625 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine plus hyaluronic acid 20mg and capsular distension
Number of subjects: 100
Study 23063625 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine plus triamcinolone 40mg IA injection
Number of subjects: 100
Study 21750266 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (1,800 mg/day) for 2 weeks
Number of subjects: 8
Study 21750266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion with ALA pretreatment
Number of subjects: 8
Study 21750266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion without ALA pretreatment
Number of subjects: 8
Study 21750266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 8
Study 19401659 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.2 mg kg(‐1) bolus, followed by infusion at 2 mg kg(‐1) h(‐1))
Number of subjects: 60
Study 19401659 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC, infusion at 5 mg kg(‐1) h(‐1))
Number of subjects: 60
Study 19401659 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 60
Study 16782569 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-portal endoscopic release (2-PER)
Number of subjects: 10
Study 16782569 — intervention group
Group type: COMPARATOR
Intervention: Open release (OR) with two minimised incisions
Number of subjects: 10
Study 15290395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative PGE1
Number of subjects: 40
Study 15290395 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative treatment (Control)
Number of subjects: 40
Study 11894980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combined continuous hormone replacement therapy (HRT) with Kliogest (oestradiol 2 mg, norethisterone 1 mg)
Number of subjects: 59
Study 11894980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9469797 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg perindopril administered at 0900 h
Number of subjects: 20
Study 9469797 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg perindopril administered at 2100 h
Number of subjects: 20
Study 9469797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8194494 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil-enriched diet
Number of subjects: 101
Study 8194494 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil-enriched diet
Number of subjects: 101
Study 3074777 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg twice a day
Number of subjects: 80
Study 31874212 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC); mean cord clamping time 5:49 ± 2:37 min; infants needed less time to reach respiratory stability (5:54 ± 2:27 min).
Number of subjects: 37
Study 31874212 — intervention group
Group type: COMPARATOR
Intervention: Standard delayed cord clamping (DCC); mean cord clamping time 1:02 ± 0:30 min; infants needed more time to reach respiratory stability (7:07 ± 2:54 min).
Number of subjects: 37
Study 29895225 — intervention group
Group type: EXPERIMENTAL
Intervention: Service screening mammography for women aged 50-64 and 45-69
Number of subjects: 0
Study 29895225 — intervention group
Group type: EXPERIMENTAL
Intervention: Service screening mammography for women aged 50-64
Number of subjects: 0
Study 29895225 — intervention group
Group type: EXPERIMENTAL
Intervention: Service screening mammography for women aged 45-49 and 65-74
Number of subjects: 0
Study 28545321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal MLV vaccine (containing BoHV-1, BRSV, BPIV-3)
Number of subjects: 20
Study 28545321 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous MLV vaccine (containing BVDV-1, BVDV-2, BoHV-1, BRSV, BPIV-3)
Number of subjects: 20
Study 28545321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal MLV vaccine
Number of subjects: 20
Study 28545321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 24646115 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL-S
Number of subjects: 41
Study 24646115 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLAD
Number of subjects: 41
Study 24646115 — intervention group
Group type: COMPARATOR
Intervention: IANB
Number of subjects: 41
Study 23062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% permethrin cream and a comprehensive scabies control programme including hygiene monitoring and health education classes.
Number of subjects: 4824
Study 23062631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 4824
Study 23062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme including hygiene practices and health education.
Number of subjects: 4824
Study 23062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme including scabies knowledge education.
Number of subjects: 4824
Study 21906391 — intervention group
Group type: EXPERIMENTAL
Intervention: azelnidipine (16 mg/day)
Number of subjects: 17
Study 21906391 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (5 mg/day)
Number of subjects: 17
Study 19231250 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal PTFE thrupass (WL Gore & Ass)
Number of subjects: 120
Study 19231250 — intervention group
Group type: COMPARATOR
Intervention: Surgical polytetrafluoroethylene (PTFE) bypass to proximal popliteal artery
Number of subjects: 120
Study 16838613 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizina
Number of subjects: 60
Study 16838613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinarizina
Number of subjects: 60
Study 16838613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12771112 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 4532
Study 12771112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4532
Study 10841241 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 61
Study 10841241 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 61
Study 9241336 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1, n = 25)
Number of subjects: 50
Study 9241336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n = 25)
Number of subjects: 50
Study 1570380 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0
Study 1570380 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg
Number of subjects: 0
Study 1570380 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 3883767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine in cardioplegic solution (average dose 407 +/- 22 micrograms at one center; 476 +/- 22 micrograms at another center)
Number of subjects: 205
Study 3883767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nifedipine)
Number of subjects: 205
Study 30312980 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's four-step approach
Number of subjects: 491
Study 30312980 — intervention group
Group type: COMPARATOR
Intervention: Traditional peer teaching
Number of subjects: 491
Study 29149381 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme (DTTP) for conventional insulin therapy in outpatient group
Number of subjects: 66
Study 29149381 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme (DTTP) for conventional insulin therapy in inpatient group
Number of subjects: 66
Study 29149381 — intervention group
Group type: COMPARATOR
Intervention: Outpatient group
Number of subjects: 66
Study 29149381 — intervention group
Group type: COMPARATOR
Intervention: Inpatient group
Number of subjects: 66
Study 29149381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 25961725 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influence manipulation during effort allocation trials
Number of subjects: 0
Study 25961725 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort allocation under low probability of reward
Number of subjects: 0
Study 25961725 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort allocation under high probability of reward
Number of subjects: 0
Study 24624850 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration with Ropivacaine
Number of subjects: 60
Study 21427150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cervical traction
Number of subjects: 79
Study 21427150 — intervention group
Group type: COMPARATOR
Intervention: Infrared irradiation alone (Control)
Number of subjects: 79
Study 19037084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg QD
Number of subjects: 16
Study 19037084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg QD
Number of subjects: 16
Study 19037084 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg BID
Number of subjects: 16
Study 19037084 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 40 mg QD
Number of subjects: 16
Study 17959549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchovaxom treatment (3.5 mg daily for 10 days every month for 3 months)
Number of subjects: 43
Study 17959549 — intervention group
Group type: COMPARATOR
Intervention: Budesonide aerosol (200 microg once or twice daily for 3 months)
Number of subjects: 43
Study 17959549 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (10 healthy infants)
Number of subjects: 43
Study 17959549 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment group (budesonide)
Number of subjects: 43
Study 15547426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electrical stimulation with Nucleus 24 cochlear implant
Number of subjects: 37
Study 11431299 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 177
Study 11431299 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 177
Study 11431299 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 177
Study 11431299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pain for longer than five years
Number of subjects: 177
Study 11431299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myofascial pain syndrome
Number of subjects: 177
Study 9849291 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 60